6-ketoprostaglandin-f1-alpha and Lymphoma--Non-Hodgkin

To determine the effect of anti-neoplastic chemotherapy on the vascular system(s) of children with leukemia/lymphoma, urinary excretion of 6-keto-PGF1 alpha was measured by radioimmunoassay (RIA). In 4 patients receiving therapy, 6-keto-PGF1 alpha increased to a mean of 148 (range; 126-170)% during therapy, then returned to pre-treatment level 3-5 days later. In 18 long-term survivors who had completed therapy, 6-keto-PGF1 alpha was determined to be a mean of 275 (range; 52-905) ng/g creatinine, and in the healthy control children the mean was 146 (range; 71-348) ng/g creatinine. These results were contrary to our hypothesis that chemotherapy might cause a decreased synthesis of PGI2, a precursor of 6-keto-PGF1 alpha, and suggest that increased urinary 6-keto-PGF1 alpha reflects a vascular response to acute exposure to chemotherapeutic drugs and possible vascular damage due to long-term intensive chemotherapy in pediatric patients with leukemia/lymphoma.

Topics: 6-Ketoprostaglandin F1 alpha; Antineoplastic Combined Chemotherapy Protocols; Child; Female; Follow-Up Studies; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Prognosis; Radioimmunoassay; Reference Values